EyePoint’s Second Wet-AMD Failure Shifts Its Funding Priorities to Diabetic Eye Disease

A second setback changes the development plan

EyePoint, a clinical-stage developer of long-acting treatments for retinal disease, announced on October 19 that DURAVYU missed the primary vision endpoint in its Phase 3 LUCIA trial. DURAVYU is designed to preserve vision while reducing injections into the eye. The second pivotal failure in wet age-related macular degeneration, or wet AMD, shifts the development strategy toward diabetic macular edema (DME), increasing dependence on the remaining program and the capital available to complete it.

The accompanying restructuring includes a workforce reduction of approximately 53% and early conclusion of the wet-AMD pivotal trials, without completing their full second year. Management expects pivotal DME results in the fourth quarter of 2027. EyePoint is therefore reducing its organization while continuing a development program with more than a year until its principal efficacy readouts.

DME has different disease characteristics from wet AMD, leaving a clinical rationale for continued development. Its pivotal trials nevertheless require DURAVYU to preserve vision comparably to aflibercept, an established injected treatment that blocks vascular endothelial growth factor, a signal involved in abnormal blood-vessel growth and leakage. The early DME study used a different aflibercept regimen and measured a different primary outcome, limiting its ability to predict the pivotal results.

Fewer injections did not establish comparable vision

DURAVYU combines vorolanib, a drug that inhibits cellular signaling involved in abnormal blood-vessel activity, with a biodegradable insert designed to release treatment for at least six months. Sustained delivery could reduce the frequency of treatment for patients with chronic retinal disease, provided vision is adequately preserved. DURAVYU remains investigational and has not received FDA approval.

Wet AMD involves abnormal blood vessels that can leak beneath the retina and damage central vision. In LUCIA, DURAVYU administered every 24 weeks was compared with aflibercept administered every eight weeks, following initial loading treatment. Supplemental aflibercept was available under specified criteria when additional treatment was needed.

The LUCIA presentation reports average vision gains of 2.5 letters for DURAVYU and 6.1 letters for aflibercept at the blended weeks 52 and 56 assessment. Letters measure performance on a standardized vision chart with the best available optical correction. EyePoint reported a model-estimated difference of negative 3.7 letters; the displayed arm averages are rounded.

The study needed to establish that DURAVYU’s vision outcome was no worse than aflibercept by more than a prespecified 4.5-letter margin. Its confidence interval extended beyond that boundary. Improvement from baseline therefore did not establish the required comparability with the active treatment.

EyePoint also reported a 38% reduction in injection burden after loading and 52% of DURAVYU-treated eyes remaining free of supplemental injections through week 56. Those patients still received scheduled DURAVYU treatment. These results demonstrate sustained drug activity, while the primary comparison leaves uncertainty about the vision outcome patients would receive in exchange for fewer injections.

The August LUGANO announcement had emphasized an additional analysis excluding nine DURAVYU patients whose large vision losses management attributed to causes unrelated to wet AMD. That analysis supported noninferiority, although the full study population missed the primary endpoint. A potential first-half 2027 regulatory submission remained conditional on LUCIA. The second failure materially reduces the support for that earlier timetable, even as EyePoint continues further analyses.

The DME evidence supports further study, with important differences

DME occurs when diabetes-damaged blood vessels leak fluid into the macula, the retinal area responsible for detailed central vision. Both vascular leakage and inflammation contribute to the disease. EyePoint’s rationale is that sustained vorolanib delivery could address these processes while reducing treatment frequency.

The earlier Phase 2 VERONA study provided evidence of activity in DME. Both DURAVYU doses achieved the primary endpoint of extending the time until a supplemental injection was required. In the 2.7-milligram group, approximately 73% of patients remained supplement-free through 24 weeks, compared with 50% in the control group.

The design differences limit how directly those results can support expectations for COMO and CAPRI.

VERONA’s high-dose and control groups contained just 11 and six patients, respectively. The later scientific presentation showed 24-week vision gains of 7.1 letters for high-dose DURAVYU and 6.9 letters for control. The small groups provide limited precision, and control patients received one initial aflibercept injection followed by supplemental treatment as needed. A similar vision gain in that setting does not establish comparability with regularly dosed aflibercept over a year.

COMO and CAPRI also include a predominantly previously untreated population. Prior treatment can affect starting vision, disease control and the scope for improvement, so VERONA’s results cannot be directly transferred to this larger population. The direction of that difference is uncertain. The pivotal studies will establish whether DURAVYU can sustain comparable vision against repeated active treatment over roughly a year, while also measuring the reduction in injection burden.

The earlier runway outlook needs a new spending plan

EyePoint estimates that restructuring and associated operational adjustments will generate approximately $30 million in annualized savings. Most workforce reductions are expected during the fourth quarter of 2026, with completion in the first half of 2027. Estimated employee-separation and related charges total approximately $9 million. Management also disclosed an estimated $118 million of cash, cash equivalents and short-term investments at September 30.

In its second-quarter filing, EyePoint said $180.5 million of cash, cash equivalents and marketable securities at June 30 would fund operations into the fourth quarter of 2027. That earlier forecast reaches the same quarter as the expected DME results, without establishing a funding buffer beyond them. October’s restructuring announcement supplied a newer liquidity estimate and planned savings, but did not update the runway date or quantify the revised spending schedule.

The remaining costs extend beyond employee compensation. EyePoint reported $155.8 million of research and development expense in the first half of 2026, driven by the wet-AMD and DME Phase 3 programs and manufacturing scale-up. Ending the wet-AMD trials early should remove future activity, while the two DME studies and their clinical-supply requirements continue. The timing of those changes, alongside the separation charges, will determine how quickly savings translate into lower cash consumption.

The disclosed figures do not support a precise revised financing requirement. A new spending forecast would show whether existing liquidity covers the late-2027 data releases with sufficient capacity for regulatory preparation and subsequent development. If additional capital is required before the results, its terms would affect how much of any eventual clinical success accrues to existing shareholders.

A narrower clinical and funding path

EyePoint retains evidence of DURAVYU activity in DME, but now depends more heavily on a single disease indication. The principal uncertainty is whether the sustained-delivery approach can preserve vision against regularly administered aflibercept in the larger pivotal studies. VERONA supports the decision to investigate that possibility, with limited ability to establish its likelihood.

Successful COMO and CAPRI vision results, accompanied by reduced injection burden, would strengthen the case for commercialization. Ahead of the expected fourth-quarter 2027 readouts, an updated runway and spending forecast would clarify the capital needed to reach them. Together, those disclosures will determine whether EyePoint can advance a clinically competitive treatment while retaining sufficient financial capacity for its next development stage.